Eastgate Biotech Corp.

ETBI

US2772531008

Pharmaceuticals

Market Closed - OTC Markets Other stock markets 07:51:18 07/06/2024 pm IST			5-day change	1st Jan Change
0.0045 ^USD	0.00%		-50.00%	-55.00%

2021	EastGate Biotech Corp., Dr. Upadhyay Vedic Research Laboratories and ImmunoJuvenate, Inc. Enter Into a 3-way International Distribution Agreement	CI
2021	EastGate Biotech Corp. Enters into A Licensing and Distribution Agreement for Glucora	CI

Eastgate Biotech Corp. Reports Earnings Results for the Third Quarter Ended September 30, 2017

March 05, 2019 at 02:40 am IST

Eastgate Biotech Corp. announced earnings results for the third quarter ended September 30, 2017. For the third quarter, the company announced sales was USD 23,138 compared to USD 0 a year ago. Operating loss was USD 1.690 million compared to USD 433,522 a year ago. Net loss was USD 1.632 million compared to USD 473,300 a year ago. Basic eps - continuing operations was USD 0 compared to basic loss per share from continuing operations of USD 0.002 a year ago. For the nine months, sales was USD 137,638 compared to USD 0 a year ago. Operating loss was USD 3.052 million compared to USD 2.291 million a year ago. Net loss was USD 3.249 million compared to USD 2.408 million a year ago. Basic loss per share from continuing operations was USD 0.01 compared to USD 0.01 a year ago.

Latest news about Eastgate Biotech Corp.

EastGate Biotech Corp., Dr. Upadhyay Vedic Research Laboratories and ImmunoJuvenate, Inc. Enter Into a 3-way International Distribution Agreement	17/21/17	CI
EastGate Biotech Corp. Enters into A Licensing and Distribution Agreement for Glucora	08/21/08	CI
EastGate Biotech Corp. and EastGate Biotech Pakistan Expands its Collaboration in Advancing the Development of a New Vaccine Against COVID-19	18/20/18	CI
Eastgate Biotech Corp. Announces Phase 3 Clinical Trials of Insurgin	06/20/06	CI
EastGate Biotech Corp. Partners with EastGate Biotech Pakistan for the International Marketing Rights of Anaferon	30/20/30	CI
EastGate Biotech Corp Expands Pipeline to Alzheimer’S Disease Using Its Alternative Insulin Delivery Platform	14/19/14	CI
Eastgate Biotech Corp. Announces Expansion and Restructuring of Joint Venture with Its Partner in Pakistan	09/19/09	CI
EastGate Biotech Receives Regulatory Approval to Initiate a Phase III 90-day Clinical Trial on Insugin, Its Liquid Insulin Mouth Rinse Solution	25/19/25	CI
Eastgate Biotech Corp. Appoints Bill Abajian as Chief Operating Officer	04/19/04	CI
EastGate Biotech Corp Announces It Has Filed an Application with the Drug Regulatory Authority of Pakistan and Ministry of National Health Services to Initiate A Phase Iii Clinical Study for Insugin	26/19/26	CI
Eastgate Biotech Announces Preparation to Initiate Phase III Clinical Trials on Insugin	15/19/15	CI
EastGate Biotech Announces Positive Phase II Clinical Results of its Innovative Liquid Insulin Mouth Rinse Solution for Type 2 Diabetes	24/19/24	CI
Eastgate Biotech Corp. Reports Earnings Results for the Third Quarter Ended September 30, 2017	05/19/05	CI
EastGate Biotech Enters into Licensing Agreement with Nico Innovapharma	29/18/29	CI
Eastgate Biotech Corp. announced that it expects to receive $2 million in funding from Nico Innovagroup S.r.l.	10/18/10	CI
Eastgate Biotech Corp. announced that it has received $0.45 million in funding	20/18/20	CI
EastGate Biotech Corp. Enters into a Memorandum of Understanding with Genluiching Mining Corporation and AAH International Associates Inc	19/18/19	CI
Eastgate Biotech Corp. announced that it expects to receive $5.8 million in funding	13/18/13	CI
Eastgate Biotech Corp. Enters into Joint Venture with AC Nova Technologies Inc	04/17/04	CI
Eastgate Biotech Corp. entered into a purchase and sale agreement to acquire OMNI Surgery + Anti-Aging Centre from Bill Abajian.	14/17/14	CI
EastGate Biotech Corp. Receives Large Order for Glucora, its Natural Glucose Management Product	05/16/05	CI
EastGate Biotech Corp. Receives Repeat Purchase Order from Preferred Nutrition Inc	06/16/06	CI
Eastgate Biotech Corp. announced that it has received $0.02 million in funding	05/15/05	CI
Eastgate Biotech Corp. Announces Commencement of Activities for its Proprietary Intraoral Insulin Tablet	29/15/29	CI
Eastgate Biotech Corp. Auditor Raises 'Going Concern' Doubt	01/15/01	CI

Chart Eastgate Biotech Corp.

Duration

Period

More charts

Company Profile

EastGate Biotech Corp. is a pharmaceutical company. The Company produces and distributes nutraceuticals that are based on natural therapies and absorbed naturally by the body. The Company utilizes nanotechnologies to deliver healthy alternatives to conventional pharmaceuticals that all too often create dangerous side effects and unexpected consequences for those trying to attain and maintain healthy lives. The Companyâs products include E-Drops NANO, Essential D, GluCora, VCleanzz, Cleanezze and Warts X. The Company also develops products in which the components are incorporated into vehicles containing nano-sized delivery vectors, including oil droplets (nanoemulsions), polymeric particles (nanoparticles) and the combination of polymers and lipids with surfactants (hybrid nanoparticles, nanocapsules, mixed micelles).

Sector

Pharmaceuticals

More about the company

Sector Other Pharmaceuticals

	1st Jan change	Capi.
EASTGATE BIOTECH CORP.	-55.00%	47.6L
ELI LILLY AND COMPANY	+45.82%	77TCr
NOVO NORDISK A/S	+40.95%	63TCr
JOHNSON & JOHNSON	-6.16%	35TCr
MERCK & CO., INC.	+19.86%	33TCr
ABBVIE INC.	+9.32%	30TCr
ASTRAZENECA PLC	+18.45%	25TCr
ROCHE HOLDING AG	-0.78%	22TCr
NOVARTIS AG	+11.88%	22TCr
AMGEN INC.	+5.90%	16TCr

Other Pharmaceuticals